CIPLABSECIPLA LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 27 Oct, 2026 · 13:22 IST

Cipla Q2 profit falls 37% as revenue slips

Revenue DeclineEbitda Margin CompressionResults RestatedExceptional ItemResults View source PDFExplain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.2%Reaction day
₹1347.10
prior close
₹1372.70
announcement price
In-mkt
timing
Nifty 100market+0.2%-0.0% vs market
Pharmaceuticals peers, median of 173sector+2.0%-1.8% vs sector

On the reaction day the stock moved in line with Nifty 100 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.3
10m
-3.4
15m
-2.6
30m
-3.2
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.2+0.2-0.0+2.0-1.8
Next day
+1.4+0.0+1.3+2.6-1.3
2d
+0.8+1.1-0.3+2.7-1.9
3d
+2.4pendingpending+1.9+0.5
4d
—————
5d
—————
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cipla's unaudited consolidated Q2 revenue from operations fell 2.4% year on year to Rs 7,403.93 crore, while net profit declined 37.1% to Rs 851.51 crore. Half-year revenue was nearly flat at Rs 14,523.21 crore, but profit fell 38.1% to Rs 1,637.06 crore. Operating cash flow remained positive at Rs 1,218.67 crore. The auditor's review was unmodified; the FY26 comparator included a Rs 275.91 crore labour-code exceptional charge.

Likely market impact

Weaker earnings may pressure the share price, though positive cash flow and a clean review offer some support.